In the field of LSDs, conventional allogeneic HSCT has performed well in treating MPS I-H, which is caused by IDUA mutations resulting in alpha-L-iduronidase deficiency and affects multiple tissues including the central nervous system (CNS). The gene discussed is IDUA; the disease is hyperinsulinemic hypoglycemia, familial, 4.